Study Assessing the Efficacy of Eductyl® for the Treatment of Patients With Dyschesia

Inclusion criteria

• Male or female aged from 18 to 75 years old,
• Writing consent to take part in the study,
• Patient with a dyschesia according to Rome III criteria
• An intensity of the inconfort using a VAS (0 (no inconfort) to 100 mm (maximal and no supportable inconfort)) equal or over 40 mm

Exclusion criteria

• Patient suffering of neurologic affection,
• Rectal diseases including :

• Current anal ou peri-anal pain,
• Current organic injury of colon or rectum,
• Current anal injury,
• Current rectal Prolapse,
• Current haemorrhoid,
• Colon inflammatory disease (ulcero haemorrhagic recto colitis, Crohn disease…),
• Current ano-recto-colon stenosis (anastomosis, scarring ...)
• Patient undergone pain killers (WHO level II (except dextropropoxyphen) and III) during the last 8 days,
• Patient undergone anti-depressants except if this treatment is regular for at least 15 days and it won't be modified during the study,
• Patient with a constipation treatment except if this treatment is regular for at least 15 days and it won't be modified during the study
• Intolerance to Eductyl® or to one of its components (potassium tartarate acid, sodium bicarbonate, solid hemisynthethic glycerides, soya lecithin, talc)
• Use of Eductyl® during the previous 15 days (over 5 days in the last 15 days),
• Patient already included in clinical trial in the last month,
• Pregnant or breast feeding woman,
• Woman of childbearing potential without contraception,
• Patient unable to read and write.